Endometrial preparation before the transfer of single, vitrified-warmed, euploid blastocysts: does the duration of estradiol treatment influence clinical outcome?

Sekhon, L.; Feuerstein, J.; Pan, Stephanie; Overbey, Jessica; Lee, Joseph A.; Briton-Jones, Christine; Flisser, E.; Stein, Daniel E.; Mukherjee, Tanmoy; Grunfeld, L.; Sandler, B.; Copperman, A.B.

doi:10.1016/j.fertnstert.2019.02.024

Cited by 37 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sekhon et al suggested duration of estradiol supplementation before progesterone in arti cial cycles did not impact frozen blastocyst transfer outcome [13]. This effect may extend beyond the route estradiol absorbed as we demonstrated that estrogen vaginally or orally administered did not impact clinical pregnancy rate and live birth rate in arti cial FET cycles.…”

Section: Discussionsupporting

confidence: 49%

“…However, the duration and dose of estradiol administration in HRT-FET cycles intervened with the clinical and neonatal outcomes. Sekhon et al have indicated that duration of estradiol supplementation before progesterone in arti cial cycles did not impact frozen blastocyst transfer outcome, but inversely correlated with gestational age [13]. Constant dose or increasing dose of estrogen in HRT for endometrium preparation though didn't change live birth rate [14], but excessive duration of estradiol priming which was more than 28 days induced slacked pregnancy rate and increased miscarriage rates in FET [15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Does Estradiol Orally and Vaginally Administered Together Impact Live Birth and Neonatal Outcome in Artificial Frozen-thawed Embryo Transfer Cycles: A Retrospective Cohort Study

Liu¹,

Yao²,

Sun³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Previous studies have demonstrated that newborns from fresh embryo transfer are with higher risk of small for gestation (SGA) rate than those from frozen-thawed embryo transfer (FET). It is suggested that supraphysiologic serum estradiol in controlled ovarian stimulation (COS)is one of reasons. Out study aims to investigate whether exogenous estradiol delivered regimens have an impact on live birth rate and singleton birthweight in hormone replacement (HRT)-FET cycles.Methods:This retrospective study involved patients undergoing their first FET with HRT endometrium preparation followed by two cleavage-staged embryos transfer, comparing orally and vaginal estradiol tablets (OVE) group versus oral estradiol tablets (OE) group from January 2015 to December 2018 at our center. A total of 792 patients fulfilled the criteria, including 282 live birth singletons. Live birth was the primary outcome. Secondary outcome included clinical pregnancy rate, singleton birthweight, large for gestational age (LGA) rate, SGA rate, preterm delivery rate. Results:Patients in OVE group achieved higher serum estradiol level with more days of estradiol treatment. No difference in live birth (Adjusted OR 1.327; 95%CI 0.982, 1.794, p=0.066) and clinical pregnancy rate (Adjusted OR 1.278; 95%CI 0.937, 1.743, p=0.121) was found between OVE and OE groups. Estradiol route did not affect birth weight (β=-30.962, SE=68.723, p=0.653), the odds of LGA (Adjusted OR 1.165; 95%CI 0.545, 2.490, p=0.694), the odds of SGA (Adjusted OR 0.569; 95%CI 0.096, 3.369, p=0.535) or the preterm delivery rate (Adjusted OR 0.969; 95%CI 0.292, 3.214, p=0.959).Conclusion:Estrogen orally and vaginally together did not have an impact on clinical outcomes and singleton birthweight compared to estrogen orally taken, but was accompanied with relative higher serum E2 level and potential maternal undesirable risks.

show abstract

Section: Discussionsupporting

confidence: 49%

Section: Introductionmentioning

confidence: 99%

Does Estradiol Orally and Vaginally Administered Together Impact Live Birth and Neonatal Outcome in Artificial Frozen-thawed Embryo Transfer Cycles: A Retrospective Cohort Study

Liu¹,

Yao²,

Sun³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Number of mouse (n) = 5. and embryo transfer (IVF-ET), and, high doses of estrogen are also used in endometrium preparation in patients underlying frozen embryo implantation (Berkane et al 2017). Several studies demonstrated that supraphysiological E 2 levels were not detrimental to IVF-ET outcomes (Jing et al 2019, Sekhon et al 2019, although previous studies suggested that exposure to high levels of E 2 during IVF treatment in the early follicular phase might be related to a lower chance of pregnancy and IVF outcome (Kolibianakis et al 2003). Our previous study and the present studies also showed that 10 −7 M E 2 promoted JAr spheroid attachment on IK cells (Ullah et al 2017).…”

Section: Figurementioning

confidence: 99%

miR-183-5p regulates uterine receptivity and enhances embryo implantation

Akbar

Ullah

Rahman

et al. 2020

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

Receptive endometrium is a prerequisite for successful embryo implantation, and it follows that poor endometrial receptivity is a leading cause of implantation failure. miRNAs play important roles as epigenetic regulators of endometrial receptivity and embryo implantation through post-transcriptional modifications. However, the mechanisms of action of many miRNAs are poorly understood. In this study, we investigated the role of the miR-183 family, comprising three miRNAs (miR-183-5p, miR-182-5p, and miR-96-5p) in endometrial receptivity and embryo implantation. The miR-183 family shows estrogen-dependent upregulation in endometrial Ishikawa (IK) cells. The miR-183 family also has a positive role in migration and proliferation of IK cells. Furthermore, JAr spheroid attachment experiments show that attachment rates were significantly decreased after treatment of IK cells with inhibitors for miR-183-5p and miR-182-5p and increased after treatment with miR-183-5p-mimic and miR-96-5p-mimic, respectively. The downstream analysis shows that catenin alpha 2 (CTNNA2) is a potential target gene for miR-183-5p, and this was confirmed in luciferase reporter assays. An in vivo mouse pregnancy model shows that inhibition of miR-183-5p significantly decreases embryo implantation rates and increases CTNNA2 expression. Downregulation of CTNNA2 in endometrial cells by miR-183-5p may be significant in mediating estrogenic effects on endometrial receptivity. In conclusion, miR-183-5p and the CTNNA2 gene may be potential biomarkers for endometrial receptivity and may be useful diagnostic and therapeutic targets for successful embryo implantation.

show abstract

“…Several studies show that the dose of estrogen in the endometrial preparation varies between 4 and 6 mg per day, with no difference in the pregnancy rate. Based on these results, our endometrial preparation protocols, regardless of the mode of administration, were performed with a daily dose of 6mg (Sekhon et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

A comparison of the effects of three different estrogen used for endometrium preparation on the outcome of day 5 frozen embryo transfer cycle

Scheffer¹,

Scheffer²,

Aguiar³

et al. 2020

JBRA Assisted Reproduction

View full text Add to dashboard Cite

Objective: To evaluate the effects of three different estrogen used for endometrium preparation on pregnancy rate, as well as hormone profile on day 5 frozen embryo transfer (FET) cycles. Methods: Retrospective, observational study. Setting: A tertiary teaching and research private reproductive medicine center. Patients: Ninety patients who were undergoing endometrium preparation for day five frozen embryo transfer cycle (FET). Intervention(s): The women were divided in three groups according to the administration route of estrogen (E2): oral (Primogyna), transdermal patches (Estradot), or transdermal gel (Oestrogel Pump). These administration routines of estrogen are equivalent to 6mg of estradiol daily. All women received 600mg of vaginal progesterone (P) per day (Utrogestan) for luteal phase support. We drew blood samples on starting P day, as well as on beta hCG day for E2 and P measurements. Main Outcome Measure(s): Clinical pregnancy rates (PR). Results: Patient features in the three groups were comparable. There were no significant differences concerning implantation rate, clinical PR, miscarriage rate, multiple-pregnancy rate, or E2 and P levels on starting P day and on beta hCG day. Conclusions: In FET cycles with oral (Primogyna) or transdermal patches (Estradot), or transdermal gel (Oestrogel Pump), there was no significant difference on pregnancy rates.

show abstract

Endometrial preparation before the transfer of single, vitrified-warmed, euploid blastocysts: does the duration of estradiol treatment influence clinical outcome?

Cited by 37 publications

References 24 publications

Does Estradiol Orally and Vaginally Administered Together Impact Live Birth and Neonatal Outcome in Artificial Frozen-thawed Embryo Transfer Cycles: A Retrospective Cohort Study

Does Estradiol Orally and Vaginally Administered Together Impact Live Birth and Neonatal Outcome in Artificial Frozen-thawed Embryo Transfer Cycles: A Retrospective Cohort Study

miR-183-5p regulates uterine receptivity and enhances embryo implantation

A comparison of the effects of three different estrogen used for endometrium preparation on the outcome of day 5 frozen embryo transfer cycle

Contact Info

Product

Resources

About